img

Global Dry Age-Related Macular Degeneration Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Dry Age-Related Macular Degeneration Market Research Report 2024

Dry macular degeneration is a common eye disorder among people over 50. It causes blurred or reduced central vision, due to thinning of the macula (MAK-u-luh). The macula is the part of the retina responsible for clear vision in your direct line of sight.
According to Mr Accuracy reports new survey, global Dry Age-Related Macular Degeneration market is projected to reach US$ 2147.9 million in 2029, increasing from US$ 1386 million in 2022, with the CAGR of 6.5% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Dry Age-Related Macular Degeneration market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Dry Age-Related Macular Degeneration market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Santen Pharmaceuticals
Allergan
Bausch Health
Alimera Science
Phio Pharmaceuticals
Ocumension Therapeutics
Belite Bio
Kubota Vision
Iveric Bio
Eyestem Research
Y2 Solution
Stealth Biotherapeutics
Segment by Type
Oral
Injectables

Segment by Application


Above 40 Years
Above 60 Years
Above 75 Years
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Dry Age-Related Macular Degeneration report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Dry Age-Related Macular Degeneration Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oral
1.2.3 Injectables
1.3 Market by Application
1.3.1 Global Dry Age-Related Macular Degeneration Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Above 40 Years
1.3.3 Above 60 Years
1.3.4 Above 75 Years
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Dry Age-Related Macular Degeneration Market Perspective (2018-2029)
2.2 Dry Age-Related Macular Degeneration Growth Trends by Region
2.2.1 Global Dry Age-Related Macular Degeneration Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Dry Age-Related Macular Degeneration Historic Market Size by Region (2018-2024)
2.2.3 Dry Age-Related Macular Degeneration Forecasted Market Size by Region (2024-2029)
2.3 Dry Age-Related Macular Degeneration Market Dynamics
2.3.1 Dry Age-Related Macular Degeneration Industry Trends
2.3.2 Dry Age-Related Macular Degeneration Market Drivers
2.3.3 Dry Age-Related Macular Degeneration Market Challenges
2.3.4 Dry Age-Related Macular Degeneration Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Dry Age-Related Macular Degeneration Players by Revenue
3.1.1 Global Top Dry Age-Related Macular Degeneration Players by Revenue (2018-2024)
3.1.2 Global Dry Age-Related Macular Degeneration Revenue Market Share by Players (2018-2024)
3.2 Global Dry Age-Related Macular Degeneration Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Dry Age-Related Macular Degeneration Revenue
3.4 Global Dry Age-Related Macular Degeneration Market Concentration Ratio
3.4.1 Global Dry Age-Related Macular Degeneration Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Dry Age-Related Macular Degeneration Revenue in 2022
3.5 Dry Age-Related Macular Degeneration Key Players Head office and Area Served
3.6 Key Players Dry Age-Related Macular Degeneration Product Solution and Service
3.7 Date of Enter into Dry Age-Related Macular Degeneration Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Dry Age-Related Macular Degeneration Breakdown Data by Type
4.1 Global Dry Age-Related Macular Degeneration Historic Market Size by Type (2018-2024)
4.2 Global Dry Age-Related Macular Degeneration Forecasted Market Size by Type (2024-2029)
5 Dry Age-Related Macular Degeneration Breakdown Data by Application
5.1 Global Dry Age-Related Macular Degeneration Historic Market Size by Application (2018-2024)
5.2 Global Dry Age-Related Macular Degeneration Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Dry Age-Related Macular Degeneration Market Size (2018-2029)
6.2 North America Dry Age-Related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Dry Age-Related Macular Degeneration Market Size by Country (2018-2024)
6.4 North America Dry Age-Related Macular Degeneration Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Dry Age-Related Macular Degeneration Market Size (2018-2029)
7.2 Europe Dry Age-Related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Dry Age-Related Macular Degeneration Market Size by Country (2018-2024)
7.4 Europe Dry Age-Related Macular Degeneration Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Dry Age-Related Macular Degeneration Market Size (2018-2029)
8.2 Asia-Pacific Dry Age-Related Macular Degeneration Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Dry Age-Related Macular Degeneration Market Size by Region (2018-2024)
8.4 Asia-Pacific Dry Age-Related Macular Degeneration Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Dry Age-Related Macular Degeneration Market Size (2018-2029)
9.2 Latin America Dry Age-Related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Dry Age-Related Macular Degeneration Market Size by Country (2018-2024)
9.4 Latin America Dry Age-Related Macular Degeneration Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Dry Age-Related Macular Degeneration Market Size (2018-2029)
10.2 Middle East & Africa Dry Age-Related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Country (2018-2024)
10.4 Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Santen Pharmaceuticals
11.1.1 Santen Pharmaceuticals Company Detail
11.1.2 Santen Pharmaceuticals Business Overview
11.1.3 Santen Pharmaceuticals Dry Age-Related Macular Degeneration Introduction
11.1.4 Santen Pharmaceuticals Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.1.5 Santen Pharmaceuticals Recent Development
11.2 Allergan
11.2.1 Allergan Company Detail
11.2.2 Allergan Business Overview
11.2.3 Allergan Dry Age-Related Macular Degeneration Introduction
11.2.4 Allergan Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.2.5 Allergan Recent Development
11.3 Bausch Health
11.3.1 Bausch Health Company Detail
11.3.2 Bausch Health Business Overview
11.3.3 Bausch Health Dry Age-Related Macular Degeneration Introduction
11.3.4 Bausch Health Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.3.5 Bausch Health Recent Development
11.4 Alimera Science
11.4.1 Alimera Science Company Detail
11.4.2 Alimera Science Business Overview
11.4.3 Alimera Science Dry Age-Related Macular Degeneration Introduction
11.4.4 Alimera Science Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.4.5 Alimera Science Recent Development
11.5 Phio Pharmaceuticals
11.5.1 Phio Pharmaceuticals Company Detail
11.5.2 Phio Pharmaceuticals Business Overview
11.5.3 Phio Pharmaceuticals Dry Age-Related Macular Degeneration Introduction
11.5.4 Phio Pharmaceuticals Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.5.5 Phio Pharmaceuticals Recent Development
11.6 Ocumension Therapeutics
11.6.1 Ocumension Therapeutics Company Detail
11.6.2 Ocumension Therapeutics Business Overview
11.6.3 Ocumension Therapeutics Dry Age-Related Macular Degeneration Introduction
11.6.4 Ocumension Therapeutics Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.6.5 Ocumension Therapeutics Recent Development
11.7 Belite Bio
11.7.1 Belite Bio Company Detail
11.7.2 Belite Bio Business Overview
11.7.3 Belite Bio Dry Age-Related Macular Degeneration Introduction
11.7.4 Belite Bio Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.7.5 Belite Bio Recent Development
11.8 Kubota Vision
11.8.1 Kubota Vision Company Detail
11.8.2 Kubota Vision Business Overview
11.8.3 Kubota Vision Dry Age-Related Macular Degeneration Introduction
11.8.4 Kubota Vision Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.8.5 Kubota Vision Recent Development
11.9 Iveric Bio
11.9.1 Iveric Bio Company Detail
11.9.2 Iveric Bio Business Overview
11.9.3 Iveric Bio Dry Age-Related Macular Degeneration Introduction
11.9.4 Iveric Bio Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.9.5 Iveric Bio Recent Development
11.10 Eyestem Research
11.10.1 Eyestem Research Company Detail
11.10.2 Eyestem Research Business Overview
11.10.3 Eyestem Research Dry Age-Related Macular Degeneration Introduction
11.10.4 Eyestem Research Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.10.5 Eyestem Research Recent Development
11.11 Y2 Solution
11.11.1 Y2 Solution Company Detail
11.11.2 Y2 Solution Business Overview
11.11.3 Y2 Solution Dry Age-Related Macular Degeneration Introduction
11.11.4 Y2 Solution Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.11.5 Y2 Solution Recent Development
11.12 Stealth Biotherapeutics
11.12.1 Stealth Biotherapeutics Company Detail
11.12.2 Stealth Biotherapeutics Business Overview
11.12.3 Stealth Biotherapeutics Dry Age-Related Macular Degeneration Introduction
11.12.4 Stealth Biotherapeutics Revenue in Dry Age-Related Macular Degeneration Business (2018-2024)
11.12.5 Stealth Biotherapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Dry Age-Related Macular Degeneration Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Oral
Table 3. Key Players of Injectables
Table 4. Global Dry Age-Related Macular Degeneration Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Dry Age-Related Macular Degeneration Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Dry Age-Related Macular Degeneration Market Size by Region (2018-2024) & (US$ Million)
Table 7. Global Dry Age-Related Macular Degeneration Market Share by Region (2018-2024)
Table 8. Global Dry Age-Related Macular Degeneration Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Dry Age-Related Macular Degeneration Market Share by Region (2024-2029)
Table 10. Dry Age-Related Macular Degeneration Market Trends
Table 11. Dry Age-Related Macular Degeneration Market Drivers
Table 12. Dry Age-Related Macular Degeneration Market Challenges
Table 13. Dry Age-Related Macular Degeneration Market Restraints
Table 14. Global Dry Age-Related Macular Degeneration Revenue by Players (2018-2024) & (US$ Million)
Table 15. Global Dry Age-Related Macular Degeneration Market Share by Players (2018-2024)
Table 16. Global Top Dry Age-Related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dry Age-Related Macular Degeneration as of 2022)
Table 17. Ranking of Global Top Dry Age-Related Macular Degeneration Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Dry Age-Related Macular Degeneration Revenue (CR5 and HHI) & (2018-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Dry Age-Related Macular Degeneration Product Solution and Service
Table 21. Date of Enter into Dry Age-Related Macular Degeneration Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Dry Age-Related Macular Degeneration Market Size by Type (2018-2024) & (US$ Million)
Table 24. Global Dry Age-Related Macular Degeneration Revenue Market Share by Type (2018-2024)
Table 25. Global Dry Age-Related Macular Degeneration Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Dry Age-Related Macular Degeneration Revenue Market Share by Type (2024-2029)
Table 27. Global Dry Age-Related Macular Degeneration Market Size by Application (2018-2024) & (US$ Million)
Table 28. Global Dry Age-Related Macular Degeneration Revenue Market Share by Application (2018-2024)
Table 29. Global Dry Age-Related Macular Degeneration Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Dry Age-Related Macular Degeneration Revenue Market Share by Application (2024-2029)
Table 31. North America Dry Age-Related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Dry Age-Related Macular Degeneration Market Size by Country (2018-2024) & (US$ Million)
Table 33. North America Dry Age-Related Macular Degeneration Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Dry Age-Related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Dry Age-Related Macular Degeneration Market Size by Country (2018-2024) & (US$ Million)
Table 36. Europe Dry Age-Related Macular Degeneration Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Dry Age-Related Macular Degeneration Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Dry Age-Related Macular Degeneration Market Size by Region (2018-2024) & (US$ Million)
Table 39. Asia-Pacific Dry Age-Related Macular Degeneration Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Dry Age-Related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Dry Age-Related Macular Degeneration Market Size by Country (2018-2024) & (US$ Million)
Table 42. Latin America Dry Age-Related Macular Degeneration Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Dry Age-Related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Country (2018-2024) & (US$ Million)
Table 45. Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Country (2024-2029) & (US$ Million)
Table 46. Santen Pharmaceuticals Company Detail
Table 47. Santen Pharmaceuticals Business Overview
Table 48. Santen Pharmaceuticals Dry Age-Related Macular Degeneration Product
Table 49. Santen Pharmaceuticals Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 50. Santen Pharmaceuticals Recent Development
Table 51. Allergan Company Detail
Table 52. Allergan Business Overview
Table 53. Allergan Dry Age-Related Macular Degeneration Product
Table 54. Allergan Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 55. Allergan Recent Development
Table 56. Bausch Health Company Detail
Table 57. Bausch Health Business Overview
Table 58. Bausch Health Dry Age-Related Macular Degeneration Product
Table 59. Bausch Health Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 60. Bausch Health Recent Development
Table 61. Alimera Science Company Detail
Table 62. Alimera Science Business Overview
Table 63. Alimera Science Dry Age-Related Macular Degeneration Product
Table 64. Alimera Science Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 65. Alimera Science Recent Development
Table 66. Phio Pharmaceuticals Company Detail
Table 67. Phio Pharmaceuticals Business Overview
Table 68. Phio Pharmaceuticals Dry Age-Related Macular Degeneration Product
Table 69. Phio Pharmaceuticals Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 70. Phio Pharmaceuticals Recent Development
Table 71. Ocumension Therapeutics Company Detail
Table 72. Ocumension Therapeutics Business Overview
Table 73. Ocumension Therapeutics Dry Age-Related Macular Degeneration Product
Table 74. Ocumension Therapeutics Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 75. Ocumension Therapeutics Recent Development
Table 76. Belite Bio Company Detail
Table 77. Belite Bio Business Overview
Table 78. Belite Bio Dry Age-Related Macular Degeneration Product
Table 79. Belite Bio Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 80. Belite Bio Recent Development
Table 81. Kubota Vision Company Detail
Table 82. Kubota Vision Business Overview
Table 83. Kubota Vision Dry Age-Related Macular Degeneration Product
Table 84. Kubota Vision Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 85. Kubota Vision Recent Development
Table 86. Iveric Bio Company Detail
Table 87. Iveric Bio Business Overview
Table 88. Iveric Bio Dry Age-Related Macular Degeneration Product
Table 89. Iveric Bio Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 90. Iveric Bio Recent Development
Table 91. Eyestem Research Company Detail
Table 92. Eyestem Research Business Overview
Table 93. Eyestem Research Dry Age-Related Macular Degeneration Product
Table 94. Eyestem Research Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 95. Eyestem Research Recent Development
Table 96. Y2 Solution Company Detail
Table 97. Y2 Solution Business Overview
Table 98. Y2 Solution Dry Age-Related Macular Degeneration Product
Table 99. Y2 Solution Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 100. Y2 Solution Recent Development
Table 101. Stealth Biotherapeutics Company Detail
Table 102. Stealth Biotherapeutics Business Overview
Table 103. Stealth Biotherapeutics Dry Age-Related Macular Degeneration Product
Table 104. Stealth Biotherapeutics Revenue in Dry Age-Related Macular Degeneration Business (2018-2024) & (US$ Million)
Table 105. Stealth Biotherapeutics Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Dry Age-Related Macular Degeneration Market Size Comparison by Type (2024-2029) & (US$ Million)
Figure 2. Global Dry Age-Related Macular Degeneration Market Share by Type: 2022 VS 2029
Figure 3. Oral Features
Figure 4. Injectables Features
Figure 5. Global Dry Age-Related Macular Degeneration Market Size Comparison by Application (2024-2029) & (US$ Million)
Figure 6. Global Dry Age-Related Macular Degeneration Market Share by Application: 2022 VS 2029
Figure 7. Above 40 Years Case Studies
Figure 8. Above 60 Years Case Studies
Figure 9. Above 75 Years Case Studies
Figure 10. Dry Age-Related Macular Degeneration Report Years Considered
Figure 11. Global Dry Age-Related Macular Degeneration Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 12. Global Dry Age-Related Macular Degeneration Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Dry Age-Related Macular Degeneration Market Share by Region: 2022 VS 2029
Figure 14. Global Dry Age-Related Macular Degeneration Market Share by Players in 2022
Figure 15. Global Top Dry Age-Related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dry Age-Related Macular Degeneration as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Dry Age-Related Macular Degeneration Revenue in 2022
Figure 17. North America Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 18. North America Dry Age-Related Macular Degeneration Market Share by Country (2018-2029)
Figure 19. United States Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. Canada Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Europe Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Dry Age-Related Macular Degeneration Market Share by Country (2018-2029)
Figure 23. Germany Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. France Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. U.K. Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Italy Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Russia Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Nordic Countries Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Asia-Pacific Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Dry Age-Related Macular Degeneration Market Share by Region (2018-2029)
Figure 31. China Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Japan Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. South Korea Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Southeast Asia Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. India Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Australia Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Latin America Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Dry Age-Related Macular Degeneration Market Share by Country (2018-2029)
Figure 39. Mexico Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Brazil Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Middle East & Africa Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Dry Age-Related Macular Degeneration Market Share by Country (2018-2029)
Figure 43. Turkey Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Saudi Arabia Dry Age-Related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Santen Pharmaceuticals Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 46. Allergan Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 47. Bausch Health Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 48. Alimera Science Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 49. Phio Pharmaceuticals Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 50. Ocumension Therapeutics Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 51. Belite Bio Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 52. Kubota Vision Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 53. Iveric Bio Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 54. Eyestem Research Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 55. Y2 Solution Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 56. Stealth Biotherapeutics Revenue Growth Rate in Dry Age-Related Macular Degeneration Business (2018-2024)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed